APhA Foundation, PrescribeWellness partner to improve diabetes management
ORLANDO, Fla. — At the American Pharmacists Association Convention on Thursday, PrescribeWellness announced a partnership with the APhA Foundation to provide community pharmacies new tools to help their diabetic patients improve their disease management and health.
The partnership combines PeakWellness, the patient engagement technology from PrescribeWellness, with the Patient Self-Management Credential from the APhA Foundation. The credential has most recently been validated with Project: Impact Diabetes, a national diabetes self-management program that brings interdisciplinary care including pharmacists to underserved communities that are highly affected by diabetes.
The PeakWellness technology solution is designed to allow for a patient-centered, decision-based approach that leads to more successful diabetes management outcomes. The program uses digital, group or one-on-one diabetes counseling leveraging the APhA Foundation’s PSMC, which increases the likelihood of positive behavioral action and engagement of patients receiving diabetes treatment.
“For over a decade, pharmacists participating in our research projects have demonstrated the value of the PSMC in customizing diabetes education to fit the needs of each patient,” said APhA Foundation executive director Mindy Smith. “We are thrilled to be working with PrescribeWellness to expand the use of the PSMC with their community pharmacy customer base so pharmacists have tools to help them more effectively help patients with diabetes manage their illness and improve health outcomes.”
“Pharmacists play a vital role in preventive care, and their participation is critical to improving healthcare outcomes and lowering overall healthcare costs,” added Al Babbington, PrescribeWellness CEO. “With the implementation of the Affordable Care Act, the American healthcare system is shifting. It’s imperative for community pharmacies to build patient relationships, focusing on adherence and chronic disease management, while using the right tools and technology.”
All free clear brand gets new addition
WILTON, Conn. — Sun Products Corp. announced the introduction of new all free clear fabric softener and dryer sheets, which will complement the company’s all free clear detergent.
“Only the No. 1-recommended detergent brand for sensitive skin can bring this kind of credibility to the fabric softener aisle,” said Elisa Gurevich, senior brand manager, all free clear. “This new sensitive skin laundry regimen allows families with sensitive skin to have clean, soft, and virtually static free laundry without the worry of skin irritation from fragrances and dyes.”
The new fabric softener and dryer sheets are available in the fabric softeners section of most major retailers. Other brands in the Sun Products Corp. portfolio include Snuggle, Wisk, Sun, Surf and Sunlight.
Indiana establishes rules for the substitution of interchangeable biologic medicines
INDIANAPOLIS — Indiana Governor Mike Pence earlier this week signed legislation designed to create a pathway for the substitution of interchangeable biologic medicines, according to published reports.
The bill allows a pharmacist to substitute an interchangeable biosimilar product for a prescribed biological product if certain conditions are met. It requires the board of pharmacy to maintain a website that lists the biosimilar biological products that are determined to be interchangeable.
The specific conditions include:
- The biosimilar product has been determined by the Food and Drug Administration to be interchangeable with the prescribed biological product;
- The prescribing practitioner has, for a written prescription, signed on the line under which the words "may substitute" appear, or for an electronically transmitted prescription, electronically transmitted the instruction "May substitute.";
- The pharmacist must inform the customer of the substitution;
- The pharmacist must notify the prescribing practitioner within five calendar days of the substitution; and
- The pharmacy and the prescribing practitioner must retain a written or electronic record of the interchangeable biosimilar substitution for at least five years.